市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Celcuity Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.8
| 分析师共识 | -1.5 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.75 |
|
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 13.21% |
| 机构持股比例 | 81.78% |
| 52周波幅 | ||
| 中 | 122.00 (-1.98%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Needham | 10 Mar 2026 | 122.00 (-1.98%) | 购买 | 117.10 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合